Raymond James & Associates Repligen Corp Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Repligen Corp stock. As of the latest transaction made, Raymond James & Associates holds 82,277 shares of RGEN stock, worth $10.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

82,277

Previous 55,119 49.27%

Holding current value

$10.3 Million

Previous $6.95 Million 76.22%

% of portfolio

0.01%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$119.79 - $167.35 $3.25 Million - $4.54 Million	27,158 Added 49.27%	82,277 $12.2 Million
Q2 2024 Jul 19, 2024	BUY	$120.0 - $182.95 $234,120 - $356,935	1,951 Added 3.67%	55,119 $6.95 Million
Q1 2024 Apr 22, 2024	BUY	$170.78 - $208.42 $1.1 Million - $1.34 Million	6,444 Added 13.79%	53,168 $9.78 Million
Q4 2023 Jan 16, 2024	SELL	$114.17 - $185.35 $2.34 Million - $3.8 Million	-20,495 Reduced 30.49%	46,724 $8.4 Million
Q3 2023 Oct 24, 2023	BUY	$138.78 - $176.51 $316,834 - $402,972	2,283 Added 3.52%	67,219 $10.7 Million
Q2 2023 Jul 25, 2023	SELL	$138.42 - $180.31 $1.49 Million - $1.93 Million	-10,731 Reduced 14.18%	64,936 $9.19 Million
Q1 2023 Apr 14, 2023	SELL	$154.26 - $198.1 $1.73 Million - $2.23 Million	-11,244 Reduced 12.94%	75,667 $12.7 Million
Q4 2022 Feb 08, 2023	SELL	$162.42 - $220.56 $85,920 - $116,676	-529 Reduced 0.6%	86,911 $14.7 Million
Q3 2022 Oct 25, 2022	SELL	$160.42 - $256.21 $1.12 Million - $1.79 Million	-6,973 Reduced 7.39%	87,440 $16.4 Million
Q2 2022 Aug 12, 2022	BUY	$140.68 - $188.02 $3.77 Million - $5.04 Million	26,791 Added 39.62%	94,413 $15.3 Million
Q1 2022 May 11, 2022	BUY	$161.19 - $257.96 $4.57 Million - $7.31 Million	28,324 Added 72.07%	67,622 $12.7 Million
Q4 2021 Feb 08, 2022	SELL	$247.59 - $304.47 $266,654 - $327,914	-1,077 Reduced 2.67%	39,298 $10.4 Million
Q3 2021 Nov 02, 2021	BUY	$194.77 - $324.21 $507,765 - $845,215	2,607 Added 6.9%	40,375 $11.7 Million
Q2 2021 Aug 11, 2021	SELL	$165.87 - $220.95 $8,127 - $10,826	-49 Reduced 0.13%	37,768 $7.54 Million
Q1 2021 May 14, 2021	SELL	$180.37 - $226.26 $787,675 - $988,077	-4,367 Reduced 10.35%	37,817 $7.35 Million
Q4 2020 Feb 12, 2021	SELL	$148.08 - $206.57 $139,343 - $194,382	-941 Reduced 2.18%	42,184 $8.08 Million
Q3 2020 Nov 04, 2020	BUY	$122.51 - $158.27 $2.05 Million - $2.65 Million	16,712 Added 63.27%	43,125 $6.36 Million
Q2 2020 Jul 28, 2020	BUY	$94.33 - $140.48 $1.41 Million - $2.1 Million	14,976 Added 130.94%	26,413 $3.27 Million
Q1 2020 Apr 21, 2020	BUY	$84.96 - $109.14 $142,562 - $183,136	1,678 Added 17.19%	11,437 $1.1 Million
Q4 2019 Feb 12, 2020	SELL	$73.84 - $93.08 $30,865 - $38,907	-418 Reduced 4.11%	9,759 $903,000
Q3 2019 Nov 07, 2019	SELL	$76.65 - $95.51 $39,781 - $49,569	-519 Reduced 4.85%	10,177 $780,000
Q2 2019 Aug 06, 2019	BUY	$54.2 - $85.95 $298,316 - $473,068	5,504 Added 106.01%	10,696 $919,000
Q1 2019 May 06, 2019	BUY	$49.45 - $62.8 $256,744 - $326,057	5,192 New	5,192 $307,000

Others Institutions Holding RGEN

# of Institutions

487

Shares Held

54.4M

Call Options Held

341K

Put Options Held

235K

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $6.92B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Repligen Corp Transaction History